These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1192 related items for PubMed ID: 12543786

  • 21. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.
    Palli D, Falchetti M, Masala G, Lupi R, Sera F, Saieva C, D'Amico C, Ceroti M, Rizzolo P, Caligo MA, Zanna I, Ottini L.
    BMC Cancer; 2007 Sep 03; 7():170. PubMed ID: 17767707
    [Abstract] [Full Text] [Related]

  • 22. BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy.
    Stuppia L, Di Fulvio P, Aceto G, Pintor S, Veschi S, Gatta V, Colosimo A, Cianchetti E, Cama A, Mariani-Costantini R, Battista P, Palka G.
    Hum Mutat; 2003 Aug 03; 22(2):178-9. PubMed ID: 12872265
    [Abstract] [Full Text] [Related]

  • 23. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF, Venter DJ.
    Cancer Epidemiol Biomarkers Prev; 1999 Sep 03; 8(9):741-7. PubMed ID: 10498392
    [Abstract] [Full Text] [Related]

  • 24. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease.
    Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H, Borg A.
    Cancer Res; 1998 Apr 01; 58(7):1367-71. PubMed ID: 9537231
    [Abstract] [Full Text] [Related]

  • 25. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
    Kwiatkowska E, Teresiak M, Filas V, Karczewska A, Breborowicz D, Mackiewicz A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4452-9. PubMed ID: 14555518
    [Abstract] [Full Text] [Related]

  • 26. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U, Cecener G, Tunca B, Tasdelen I.
    Cancer Invest; 2006 Oct 01; 24(5):484-91. PubMed ID: 16939956
    [Abstract] [Full Text] [Related]

  • 27. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
    Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A, Kallioniemi OP.
    Cancer Res; 1997 Apr 01; 57(7):1222-7. PubMed ID: 9102202
    [Abstract] [Full Text] [Related]

  • 28. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N, Kotar K, Foulkes WD.
    BMC Med Genet; 2003 Aug 11; 4():7. PubMed ID: 12911837
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
    Noh JM, Choi DH, Nam SJ, Lee JE, Kim JW, Kim SW, Kang E, Lee MH, Ahn SH, Kim KS, Park SK, Haffty BG, Korea Breast Cancer Study Group.
    Breast Cancer Res Treat; 2012 Jan 11; 131(1):217-22. PubMed ID: 21847643
    [Abstract] [Full Text] [Related]

  • 32. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
    Han SH, Lee KR, Lee DG, Kim BY, Lee KE, Chung WS.
    Clin Genet; 2006 Dec 11; 70(6):496-501. PubMed ID: 17100994
    [Abstract] [Full Text] [Related]

  • 33. BRCA2 germline mutations in male breast cancer patients in the Polish population.
    Kwiatkowska E, Teresiak M, Lamperska KM, Karczewska A, Breborowicz D, Stawicka M, Godlewski D, Krzyzosiak WJ, Mackiewicz A.
    Hum Mutat; 2001 Dec 11; 17(1):73. PubMed ID: 11139248
    [Abstract] [Full Text] [Related]

  • 34. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S, Tomka M, Kovác M, Stevurková V, Zajac V.
    Neoplasma; 2006 Dec 11; 53(2):97-102. PubMed ID: 16575464
    [Abstract] [Full Text] [Related]

  • 35. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
    Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, Capelletti M, Pezzuolo D, Camisa R, Savi M, Neri TM, Ardizzoni A.
    Breast; 2007 Jun 11; 16(3):280-92. PubMed ID: 17257844
    [Abstract] [Full Text] [Related]

  • 36. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, Tapia T, Faundez P, Palma L, Riccio ME, Paredes H, Rodriguez M, Cruz A, Rousseau C, King MC, Camus M, Alvarez M, Carvallo P.
    Breast Cancer Res Treat; 2006 Jan 11; 95(1):81-7. PubMed ID: 16261400
    [Abstract] [Full Text] [Related]

  • 37. Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
    Staff S, Isola JJ, Johannsson O, Borg A, Tanner MM.
    Br J Cancer; 2001 Oct 19; 85(8):1201-5. PubMed ID: 11710835
    [Abstract] [Full Text] [Related]

  • 38. Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations.
    Seymour IJ, Casadei S, Zampiga V, Rosato S, Danesi R, Scarpi E, Falcini F, Strada M, Morini N, Naldoni C, Amadori D, Calistri D.
    Breast Cancer Res Treat; 2008 Nov 19; 112(2):343-9. PubMed ID: 18092194
    [Abstract] [Full Text] [Related]

  • 39. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy.
    Papi L, Putignano AL, Congregati C, Zanna I, Sera F, Morrone D, Falchetti M, Turco MR, Ottini L, Palli D, Genuardi M.
    Breast Cancer Res Treat; 2009 Oct 19; 117(3):497-504. PubMed ID: 18821011
    [Abstract] [Full Text] [Related]

  • 40. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA, de Foy KA, Harrington P, Pharoah P, Dunsmuir WD, Edwards SM, Gillett C, Ardern-Jones A, Dearnaley DP, Easton DF, Ford D, Shearer RJ, Kirby RS, Dowe AL, Kelly J, Stratton MR, Ponder BA, Barnes D, Eeles RA.
    Cancer Res; 2000 Aug 15; 60(16):4513-8. PubMed ID: 10969800
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 60.